In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more

Chest pain and prior heart attack is a dangerous duet in stable coronary artery disease

CLARIFY study presented in a Hot Line Session today at ESC Congress 2019 together with WCC

Coronary Artery Disease (Chronic)


Paris, France – 3 Sept 2019:  Angina in patients with a previous heart attack is linked with a poor outcome in patients with stable coronary artery disease, according to late breaking results from the CLARIFY study presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology(1) and published in the European Heart Journal (2).

The five-year results of this large registry also found that although the use of evidence-based prevention medications was good, less than 10% of patients achieved the most recent recommended targets for blood pressure and cholesterol control.

“We estimate that in Europe, around 22 million people have stable coronary artery disease,” said first author Dr Emmanuel Sorbets of Hospital Avicenne of Bobigny, France. “The clinical profile and management of these patients has changed over the last 25 years and there is little information about prognosis.”

CLARIFY was an observational and longitudinal study performed at 394 centres in 45 countries across five continents. (3,4) In 2009 to 2010, a total of 32,703 patients with stable coronary artery disease were enrolled. Stable coronary artery disease was defined as having at least one of the following: previous myocardial infarction or revascularisation more than three months ago, proven symptomatic myocardial ischaemia, and angiographic coronary stenosis greater than 50%. Patients were followed-up once a year for five years.

The five-year rate of the composite primary outcome of cardiovascular death or myocardial infarction was 8.0%. Event rates ranged from 5.5% in Asia to 10.6% in Central/South America.

In patients who had experienced a previous heart attack, those with angina had a significantly greater likelihood of the primary outcome (11.8%) compared to those without angina (8.2%). But in patients without a previous heart attack, event rates were lower and similar regardless of the presence of angina (6.3% with angina versus 6.4% without).

Dr Sorbets said: “CLARIFY confirms that patients with prior myocardial infarction are at higher risk than those without. There has always been uncertainty about the effect of angina on cardiovascular outcomes. We show for the first time that angina worsens prognosis only in patients with a previous myocardial infarction. This is an easily identifiable high-risk subset that should be targeted for more intensive preventive treatment.”

Most patients received prevention therapies regardless of their clinical profile and the geographical area in which they lived. However, few met the most recent recommended blood pressure and low-density lipoprotein (LDL) cholesterol targets. Less than one-third (29.0%) had blood pressure less than 130/80 mmHg, while just 20.9% had LDL 1.8 mmol/L (70 mg/dl) or lower. Only 7.4% achieved both goals.

“A potential explanation for the mismatch between treatment and attaining targets is that full doses may not be prescribed,” said Dr Sorbets. “A previous analysis of CLARIFY showed that just 13.3% of patients received the full dose of beta-blockers.(5) We did not collect dose information on the other therapies. Another likely possibility is that patients did not take their pills.”

The main independent predictors of the primary outcome were history of hospitalisation for heart failure (hazard ratio [HR] 2.13), current smoking (HR 1.77), atrial fibrillation (HR 1.61), living in Central/South America (HR 1.60), prior stroke (HR 1.51), prior myocardial infarction (HR 1.50), diabetes (HR 1.40), peripheral artery disease (HR 1.31), former smoking (HR 1.31), and current angina (HR 1.30).

Some 12.5% of patients were current smokers. “The rate of smoking was relatively low, given that an earlier analysis found that 46.5% of participants were former smokers,” (4) said Dr Sorbets. “Nevertheless, smoking is related to worse outcomes, so we need to keep encouraging patients to quit.”

Regarding what can be done to help stable coronary artery disease patients meet blood pressure and cholesterol targets, Dr Sorbets said: “Doctors should prescribe full doses of preventive medications, particularly in those with angina and prior myocardial infarction, who have the worst prognosis. This group will benefit from careful management of their risk factors. We also need better ways to help patients consistently take their medications and to assess their adherence.”

ENDS

Notes to editor

Notes to editors

Authors: ESC Press Office 
Mobile: +33 (0) 7 8531 2036
Email: press@escardio.org

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2019 together with the World Congress of Cardiology is #ESCCongress

Funding: The CLARIFY registry was funded by Servier. The sponsor had no role in the study design, data analysis and interpretation, or decision to submit the manuscript for publication, but assisted with the set-up, data collection, and management of the study in each country. The database was housed in the Robertson Centre for Biostatistics in the United Kingdom and all analyses were performed by academic statisticians.

Disclosures: Dr Sorbets reports personal fees and non-financial support from Astra-Zeneca, Bayer, BMS, MSD, Novartis and Servier, and reports grants from French Society of Cardiology.

References and notes

(1) CLARIFY will be discussed during:

(2) Full paper will be available during congress from press@escardio.org

(3) CLARIFY: ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease.

(4) Sorbets E, Greenlaw N, Ferrari R, et al. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. Clin Cardiol. 2017;40:797–806. doi: 10.1002/clc.22730.

(5) Sorbets E, Steg PG, Young R, et al. Beta-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40:1399–1407. doi:10.1093/eurheartj/ehy811.

About ESC Congress

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France. Explore the scientific programme.

About the European Society of Cardiology 

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2019 together with the World Congress of Cardiology. It does not necessarily reflect the opinion of the European Society of Cardiology.